Vol.

41

No.

40

October 30, 2015Oct 30, 2015

Free

DOWNLOAD THE PDF

How Much is a Drug Worth? A Provocative Model Puts a Price on Benefit

Cover Story

Free

How Much is a Drug Worth? A Provocative Model Puts a Price on Benefit

By Matthew Bin Han Ong

Eli Lilly & Co. didn't ask Dan Goldstein, an oncologist at the Winship Cancer Institute at Emory University, to price their drugs, but he volunteered his services anyway.

Conversation with The Cancer Letter

Lilly's PACE Continuous Innovation Indicators Visualize Progress and Value in Research

By Matthew Bin Han Ong

Capitol Hill

Budget Deal Eases Sequestration, Includes Medicare Site Neutrality

By Conor Hale

A Third of Hospitals Will Drop Out of 340B if HRSA Enacts New Guidance, Survey Finds

By Matthew Bin Han Ong

Recent Issues

Scroll to top

How Much is a Drug Worth? A Provocative Model Puts a Price on Benefit

Lilly's PACE Continuous Innovation Indicators Visualize Progress and Value in Research

Budget Deal Eases Sequestration, Includes Medicare Site Neutrality

A Third of Hospitals Will Drop Out of 340B if HRSA Enacts New Guidance, Survey Finds

In Brief

Helzlsouer Named NCI DCCPS Chief Medical Officer

Thomas Graves and Jeanny Aragon-Ching join Inova cancer institute

Friends of Cancer Research honors Marlene Malek, Reps. Diana DeGette and Fred Upton

MD Anderson Cancer Center expands Moon Shots Program

CureSearch for Children’s Cancer awards $260,000 in grants

Drugs & Targets

Imlygic Approved as First U.S. Oncolytic Viral Cancer Therapy

Imbruvica wins 2015 Prix Galien Award

FDA grants priority review to MCNA in certain bladder cancer patients

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login